|
MedChemExpress
onx0914 Onx0914, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/onx0914/product/MedChemExpress Average 93 stars, based on 1 article reviews
onx0914 - by Bioz Stars,
2026-02
93/100 stars
|
Buy from Supplier |
|
TargetMol
onx 0914 Onx 0914, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/onx 0914/product/TargetMol Average 93 stars, based on 1 article reviews
onx 0914 - by Bioz Stars,
2026-02
93/100 stars
|
Buy from Supplier |
|
Basler
selective inhibition onx0914 Selective Inhibition Onx0914, supplied by Basler, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/selective inhibition onx0914/product/Basler Average 90 stars, based on 1 article reviews
selective inhibition onx0914 - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
|
Adooq Bioscience LLC
onx0914 Onx0914, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/onx0914/product/Adooq Bioscience LLC Average 90 stars, based on 1 article reviews
onx0914 - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
β5i inhibitor onx0914 ![]() β5i Inhibitor Onx0914, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/β5i inhibitor onx0914/product/MedChemExpress Average 90 stars, based on 1 article reviews
β5i inhibitor onx0914 - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
|
Cayman Chemical
onx0914 ![]() Onx0914, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/onx0914/product/Cayman Chemical Average 90 stars, based on 1 article reviews
onx0914 - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: Immunoproteasome function is inhibited in α-Syn overexpressed SH-SY5Y cells and A53T α-Syn transgenic mice. (A) Cluster of gene expression profiles in WT α-Syn or A53T α-Syn overexpressed SH-SY5Y cells graphed as heatmap. (B) The constitution of 20S core particle of immunoproteasome and DEGs associated with immunoproteasome β1i (PSMB9) , β2i (PSMB10) , and β5i (PSMB8) were visualized using heatmap. The protein levels of immunoproteasome β1i, β2i and β5i subunits were determined by Western blot in SH-SY5Y cells (C, D) and in the SN of A53T α-Syn transgenic mice (G – J) . Chymotrypsin-like (E, K) and trypsin-like (F, L) activity were measured by fluorescence from the breakdown of Suc-LLVY-AMC and Z-ARR-AMC fluorogenic substrate, respectively. * P < 0.05, ** P < 0.01.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and
Techniques: Transgenic Assay, Gene Expression, Western Blot, Activity Assay, Fluorescence
Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: β5i interacts with PLK2 and participates in its degradation. (A, B) Endogenous interactions between β5i and PLK2 were determined in SH-SY5Y cells immunoprecipitated with anti-β5i or anti-PLK2 antibody and analyzed by Western blot to detect PLK2 and β5i protein levels. (C, D) SH-SY5Y cells were transfected with the indicated plasmids. The interactions between β5i and PLK2 were determined by immunoprecipitation with anti-HA or anti-Myc antibody and analyzed by Western blot with the indicated antibodies. (E, F) The mRNA levels of PLK2 in SH-SY5Y cells with β5i overexpression or β5i knockdown were determined by real-time PCR. (G, H) The ubiquitylation levels of PLK2 in SH-SY5Y cells with β5i overexpression or β5i knockdown were examined by in vitro ubiquitin conjugation assay. The protein levels of PLK2 in SH-SY5Y cells with β5i overexpression (I, J) or β5i knockdown (K, L) were determined by Western blot. The half-life of PLK2 was assesses in SH-SY5Y cells with β5i overexpression (M, N) or β5i knockdown (O, P) treated with 10 μg/mL CHX for the indicated time. * P < 0.05.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and
Techniques: Immunoprecipitation, Western Blot, Transfection, Over Expression, Knockdown, Real-time Polymerase Chain Reaction, In Vitro, Ubiquitin Proteomics, Conjugation Assay
Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: Immunoproteasome deficiency induces α-Syn phosphorylation and accumulation. (A) Immunostaining of pS129 α-Syn in WT α-Syn or A53T α-Syn transfected SH-SY5Y cells. The protein levels of PLK2, pS129 α-Syn in β5i overexpressed SH-SY5Y cells in the presence or absence of BI 2536 (B – D) and in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression (E – G) . (H) Immunofluorescence was applied to observe nigral pS129 α-Syn in 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression. The soluble and insoluble α-Syn in β5i overexpressed SH-SY5Y cells in the presence or absence of BI 2536 (I, J) and in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression (K, L) . (M) The aggregation of α-Syn was detected by ThT immunofluorescence in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression. Representative immunofluorescent images of TH staining (N) and stereological quantification of TH-positive neurons (O) in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression. (P, Q) western blot was conducted to detect nigral TH protein levels in 12-month A53T α-Syn transgenic mice with dopaminergic neurons-specific β5i overexpression. Scale bar = 100 μm * P < 0.05, ** P < 0.01, *** P < 0.001.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and
Techniques: Phospho-proteomics, Immunostaining, Transfection, Transgenic Assay, Over Expression, Immunofluorescence, Staining, Western Blot
Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: Loss of POMP induced by α-Syn disturbs immunoproteasome β-ring assembly. POMP mRNA and protein levels in WT α-Syn or A53T α-Syn transfected SH-SY5Y cells (A – C) and in the SN of 12-month A53T α-Syn transgenic mice (D – F) . (G) The interaction between β1i, β5i precursors and POMP in SH-SY5Y cells was examined immunoprecipitated with anti-Myc antibody. The whole-cell lysate was subjected to immunoblot with anti-β1i, anti-β5i and anti-Myc antibody. (H) The interaction between β5i precursor and POMP was detected in WT α-Syn or A53T α-Syn transfected SH-SY5Y cells immunoprecipitated with anti-Myc antibody. The whole-cell lysate was subjected to immunoblot with anti-β5i, anti-Myc and anti-Flag antibody. (I–K) The protein levels of β1i and β5i were determined by Western blot in WT α-Syn or A53T α-Syn transfected SH-SY5Y cells with POMP knockdown. (L, M) Chymotrypsin-like and trypsin-like activity were measured in WT α-Syn or A53T α-Syn transfected SH-SY5Y cells with POMP knockdown. * P < 0.05.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and
Techniques: Transfection, Transgenic Assay, Immunoprecipitation, Western Blot, Knockdown, Activity Assay
Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: Dopaminergic neurons-specific overexpression of NRF2-POMP axis alleviates α-Syn pathology. (A) Homo sapiens POMP promoter contains NRF2 binding region (TGCTGTGTCAC) and ARE sequence (TGAGCGGCG). (B, C) Dual-luciferase reporter assay was applied to detect the interaction between POMP promoter and NRF2. (D – H) Western blot was applied to detect the nigral protein levels of β1i, β5i, PLK2, pS129 α-Syn in 12-month A53T α-Syn transgenic mice with dopaminergic neurons overexpressing NRF2 or POMP. (I, J) The soluble and insoluble α-Syn levels were detected in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons overexpressing NRF2 or POMP. (K) α-Syn aggregation was detected by ThT immunofluorescence in the SN of 12-month A53T α-Syn transgenic mice with dopaminergic neurons overexpressing NRF2 or POMP. (L, M) Western blot was applied to detect the nigral TH in 12-month A53T α-Syn transgenic mice with dopaminergic neurons overexpressing NRF2 or POMP. (N) Rotarod test was used to evaluate the motor ability in 12-month A53T transgenic mice with dopaminergic neurons-specific overexpression of NRF2-POMP axis. * P < 0.05, ** P < 0.01, *** P < 0.001.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and
Techniques: Over Expression, Binding Assay, Sequencing, Luciferase, Reporter Assay, Western Blot, Transgenic Assay, Immunofluorescence